NCT03463876View on ClinicalTrials.gov

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

PHASE2CompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

SHR 1210+apatinib

SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.

Trial Locations (1)

100071

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03463876 - A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) | Biotech Hunter | Biotech Hunter